Anti-Tumor Necrosis Factor-α Monotherapy Versus Combination Therapy with an Immunomodulator in IBD

Gastroenterology Clinics of North America

Volumn 43, Issue 3, 2014, Pages 441-456

  Dulai, Parambir S ^a   Siegel, Corey A ^a   Peyrin Biroulet, Laurent ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Anti TNF; Combination therapy; Immunomodulator; Monotherapy

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; GOLIMUMAB; IMMUNOMODULATING AGENT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY PRODUCTION; CANCER RISK; COLON RESECTION; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; GERIATRIC PATIENT; HIGH RISK PATIENT; HUMAN; IMMUNOGENICITY; INFECTION RISK; INFLAMMATORY BOWEL DISEASE; MEDICAL DECISION MAKING; MONOTHERAPY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT DECISION MAKING; PERSONALIZED MEDICINE; PREGNANCY OUTCOME; PREGNANT WOMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DRUG COMBINATION; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASES; PATIENT PARTICIPATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; METHOTREXATE; PATIENT PARTICIPATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84905750048     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2014.05.009     Document Type: Review

References (77)

1. Emery P., Sebba A., Huizinga T.W. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis 2013, 72:1897-1904.
2. D'Haens G., Baert F., van Assche G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
3. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
4. Panaccione R., Ghosh S., Middleton S., et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014, 146:392-400.e3.
5. Kotlyar D.S., Osterman M.T., Diamond R.H., et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011, 9:36-41.e1.
6. Stallmach A., Hagel S., Gharbi A., et al. Medical and surgical therapy of inflammatory bowel disease in the elderly-prospects and complications. J Crohns Colitis 2011, 5:177-188.
7. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
8. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
9. Rutgeerts P., Feagan B.G., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
10. Nanda K.S., Cheifetz A.S., Moss A.C. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013, 108:40-47.
11. Colombel J.F., Sandborn W.J., Allez M., et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin Gastroenterol Hepatol 2014, 12:423-431.e1.
12. Schreiber S., Rutgeerts P., Fedorak R.N., et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005, 129:807-818.
13. Hanauer S.B., Wagner C.L., Bala M., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-553.
14. Vermeire S., Noman M., Van Assche G., et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007, 56:1226-1231.
15. Sokol H., Seksik P., Carrat F., et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010, 59:1363-1368.
16. Bouguen G., Siproudhis L., Gizard E., et al. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab. Clin Gastroenterol Hepatol 2013, 11:975-981.e1-4.
17. Ungar B., Chowers Y., Yavzori M., et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2013, [Epub ahead of print].
18. Maser E.A., Villela R., Silverberg M.S., et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
19. Seow C.H., Newman A., Irwin S.P., et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010, 59:49-54.
20. Baert F., Drobne D., Gils A., et al. Early trough levels and antibodies to infliximab predict safety and success of re-initiation of infliximab therapy. Clin Gastroenterol Hepatol 2014, [Epub ahead of print].
21. Bortlik M., Duricova D., Malickova K., et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis 2013, 7:736-743.
22. Baert F., Moortgat L., Van Assche G., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468. [quiz: e10-1].
23. Paul S., Del Tedesco E., Marotte H., et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2013, 19:2568-2576.
24. Pariente B., Pineton de Chambrun G., Krzysiek R., et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:1199-1206.
25. Imaeda H., Bamba S., Takahashi K., et al. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment. J Gastroenterol 2014, 49:674-682.
26. Karmiris K., Paintaud G., Noman M., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640.
27. Lofberg R., Louis E.V., Reinisch W., et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE. Inflamm Bowel Dis 2012, 18:1-9.
28. Reenaers C., Louis E., Belaiche J., et al. Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?. Aliment Pharmacol Ther 2012, 36:1040-1048.
29. Cohen R.D., Lewis J.R., Turner H., et al. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis 2012, 18:10-16.
30. Chaparro M., Panes J., Garcia V., et al. Long-term durability of response to adalimumab in Crohn's disease. Inflamm Bowel Dis 2012, 18:685-690.
31. Allez M., Vermeire S., Mozziconacci N., et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010, 31:92-101.
32. de Silva P.S., Nguyen D.D., Sauk J., et al. Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease. Aliment Pharmacol Ther 2012, 36:459-466.
33. Bouguen G., Levesque B.G., Pola S., et al. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014, 12:978-985.
34. Ha C., Ullman T.A., Siegel C.A., et al. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol 2012, 10:1002-1007. [quiz: e78].
35. Lichtenstein G.R., Diamond R.H., Wagner C.L., et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009, 30:210-226.
36. Sandborn W.J., Hanauer S.B., Rutgeerts P., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56:1232-1239.
37. Sandborn W.J., Feagan B.G., Stoinov S., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007, 357:228-238.
38. Sandborn W.J., Feagan B.G., Marano C., et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014, 146:96-109.e1.
39. Sandborn W.J., Feagan B.G., Marano C., et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014, 146:85-95. [quiz: e14-5].
40. Jones J., Kaplan G.G., Peyrin-Biroulet L., et al. Impact of concomitant immunomodulator treatment on efficacy and safety of anti-TNF therapy in Crohn's disease: a meta-analysis of placebo controlled trials with individual patient-level data. Gastroenterology 2013, 144:S-179.
41. Kopylov U., Al-Taweel T., Yaghoobi M., et al. Adalimumab monotherapy versus combination therapy with adalimumab and immunomodulators for Crohn's disease: a meta-analysis. Gastroenterology 2014, 146:S-201.
42. Feagan B.G., McDonald J.W., Panaccione R., et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 2014, 146:681-688.e1.
43. Panaccione R., Ghosh S., Middleton S., et al. Infliximab, azathioprine, or infliximab and azathioprine for treatment of moderate to severe ulcerative colitis: the UC success trial. Gastroenterology 2011, 140:A-202.
44. Billioud V., Sandborn W.J., Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011, 106:674-684.
45. Farrell R.J., Alsahli M., Jeen Y.T., et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003, 124:917-924.
46. Maini R.N., Breedveld F.C., Kalden J.R., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.
47. Ananthakrishnan A.N., McGinley E.L. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis 2013, 7:107-112.
48. Lichtenstein G.R., Feagan B.G., Cohen R.D., et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012, 107:1409-1422.
49. Lichtenstein G.R., Rutgeerts P., Sandborn W.J., et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012, 107:1051-1063.
50. Toruner M., Loftus E.V., Harmsen W.S., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-936.
51. Marehbian J., Arrighi H.M., Hass S., et al. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol 2009, 104:2524-2533.
52. Deepak P., Stobaugh D.J., Ehrenpreis E.D. Infectious complications of TNF-alpha inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System. J Gastrointestin Liver Dis 2013, 22:269-276.
53. Siegel C.A., Marden S.M., Persing S.M., et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009, 7:874-881.
54. Lichtenstein G.R., Feagan B.G., Cohen R.D., et al. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT registry. Am J Gastroenterol 2014, 109:212-223.
55. Beaugerie L., Brousse N., Bouvier A.M., et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009, 374:1617-1625.
56. Charpentier C., Salleron J., Savoye G., et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut 2014, 63:423-432.
57. Osterman M.T., Sandborn W.J., Colombel J.F., et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology 2014, 146:941-949.
58. Khan N., Abbas A.M., Lichtenstein G.R., et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology 2013, 145:1007-1015.e3.
59. Melmed G.Y., Spiegel B.M., Bressler B., et al. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. Clin Gastroenterol Hepatol 2010, 8:655-659.
60. Habal F.M., Huang V.W. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. Aliment Pharmacol Ther 2012, 35:501-515.
61. Mahadevan U., Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology 2006, 131:283-311.
62. Ng S.W., Mahadevan U. Management of inflammatory bowel disease in pregnancy. Expert Rev Clin Immunol 2013, 9:161-173. [quiz: 174].
63. Mahadevan U., Martin C.F., Sandler R.S., et al. 865 PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology 2012, 142:S-149.
64. Mahadevan U., Wolf D.C., Dubinsky M., et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013, 11:286-292. [quiz: e24].
65. Sokol H., Beaugerie L., Maynadie M., et al. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:2063-2071.
66. Dayharsh G.A., Loftus E.V., Sandborn W.J., et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002, 122:72-77.
67. Magro F., Santos-Antunes J., Albuquerque A., et al. Epstein-Barr virus in inflammatory bowel disease-correlation with different therapeutic regimens. Inflamm Bowel Dis 2013, 19:1710-1716.
68. Solomon D.H., Kremer J.M., Fisher M., et al. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 2014, 43:489-497.
69. Clarke K., Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 2012, 18:174-179.
70. Van Assche G., Magdelaine-Beuzelin C., D'Haens G., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008, 134:1861-1868.
71. Louis E., Mary J.Y., Vernier-Massouille G., et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012, 142:63-70.e5. [quiz: e31].
72. Brandse J.F., Peters C.P., Gecse K.B., et al. Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn's disease. Inflamm Bowel Dis 2014, 20:251-258.
73. Siegel C.A. Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. Gut 2012, 61:459-465.
74. Elwyn G., Lloyd A., Joseph-Williams N., et al. Option Grids: shared decision making made easier. Patient Educ Couns 2013, 90:207-212.
75. Dulai P.S., Siegel C.A., Dubinsky M.C. Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2013, 19:2927-2936.
76. Siegel C.A., Siegel L.S., Hyams J.S., et al. Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis 2011, 17:30-38.
77. Siegel C.A., Horton H., Siegel L.S., et al. A validated web-based patient communication tool to display individualized Crohn's disease predicted outcomes based on clinical, serological and genetic variables. Gastroenterology 2014, 146. S-433-4.